Careers  |  Sign In  |  Register  |   Twitter
 
Course List

  • CME Front Matter

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.

Target Audience

The intended audience for the activity is cardiologists, interventional cardiologists, vascular medicine specialists, internal medicine physicians, family practice physicians, and other health care professionals involved in the treatment of patients with a history of atherothrombotic disease.

Learning Objectives

Upon successful completion of this video series, participants should be better able to:

  • Explain the rationale for the use of antiplatelet agents for the secondary prevention of thrombotic cardiovascular events.

  • Assess the safety and efficacy of anti-platelet therapy in reducing the rate of cardiovascular death, myocardial infarction, and stroke as well as reducing the need for coronary revascularization.

Activity Chair

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor, Department of Neurosciences
Professor of Medicine, Harvard Medical School
Boston, MA

Faculty

Marc P. Bonaca, MD, MPH
Investigator TIMI Study Group
Vascular Medicine Section, Cardiovascular Division
Brigham and Women’s Hospital Heart & Vascular Center
Boston, MA

David A. Morrow, MD, MPH
Director, Samuel A. Levine Cardiac Unit
Professor of Medicine
Harvard Medical School, Brigham & Woman's Hospital
Boston, MA

E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
Associate Director Duke Heart Center – Cardiology Clinics
Director, Program for Advanced Coronary Disease
Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™, 0.25 credits per video for Interviews #1-3 and 0.5 credits for Interview #4. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 21, 2015 to October 21, 2016.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering correctly 2 out of 3 posttest questions for each video. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Planning Committee and Faculty

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Marc P. Bonaca, MD, MPH
David A. Morrow, MD, MPH
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI

External Reviewer

David Davidson, MD

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

  • Planning Committee and Faculty members report the following relationship(s):

    • Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
      • Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi-Aventis, The Medicines Company

    • Marc P. Bonaca, MD, MPH
      • Consulting Fee: AstraZeneca, Bayer, Merck

    • David A. Morrow, MD, MPH
      • Consulting Fee: diaDexus, Eli Lilly, Gilead, Merck, Novartis, Radiometer
      • Research Funding (paid to institution): Abbott Diagnostics, Amgen, AstraZeneca, Anthera, Beckman Coulter, BG Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Eisai, GlaxoSmithKline, Johnson & Johnson, Merck, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Randox, Roche Diagnostics, Sanofi-Aventis, Siemens, Singulex

    • E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
      • Consulting Fee: Abiomed, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals, Stealth Peptides, The Medicines Company, WebMD
      • Contracted Research (paid to institution): Bayer, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals

  • External Reviewer reports the following relationship(s):

    • David Davidson, MD
      • Consulting Fee: Sanofi/Regeneron
      • Contracted Research: AstraZeneca, Bayer, Pfizer

  • Vindico Medical Education staff report the following relationship(s):
    • No relevant financial relationships to disclose.

  • Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Overview

The prevention of thrombotic cardiovascular disease – the leading cause of morbidity and mortality in the United States – is crucial, as this condition results in an average of 1 death every 40 seconds. Fatal cardiovascular events are 2.5 times more likely to occur in patients with a prior myocardial infarction. Clinical trial evidence suggests that long-term therapy with antiplatelet agents plus lifestyle modifications can reduce the risk of secondary cardiac events.

In this CME activity, leading experts discuss the safety, efficacy, and rationale for the use of antiplatelet agents in high-risk patients for the secondary prevention of thrombotic cardiovascular events, as well as those with peripheral vascular disease.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@VindicoCME.com